Based on these findings, on September 30, 2022, the FDA granted accelerated approval for futibatinib for adult patients with previously treated locally advanced or metastatic iCCA with FGFR2 gene fusion or rearrangement [20]. This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.